Evotec Se logo

Evotec Se(OTC) EVOTF

Market Cap$590.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-8%
5 Year-94%
1 Year-54%
1 Month-15%
$3.33
+0.00%
+0.00Today
Evotec Se last closing stock price
MetricPriceDate
Last closeUSD 3.332026-10-09
Evotec Se stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-14.54%USD 3.892026-09-29
1 month-14.54%USD 3.892026-08-13
3 month-50.3%USD 6.692026-06-02
Year to date-58.49%USD 8.012025-12-26
1 year-54.3%USD 7.282025-09-16
3 year-83.21%USD 19.802023-10-02
5 year-93.51%USD 51.252021-10-08
Since inception-7.64%USD 3.602004-07-23

Evotec Se Financials at a Glance

Market Cap

$590.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€717.57M

Net Income (TTM)

-€197.45M

EPS (TTM)

-$1.30

P/E Ratio

-2.57

Dividend

$0.00

Beta (Volatility)

0.12 (Low)

Price

$3.33

Volume

77,698

Open

$3.33

Previous Close

$3.33

Daily Range

$3.33 - $3.33

52-Week Range

$3.33 - $8.36

Estimated Earnings Date

Nov 5, 2026

EVOTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Evotec Se

Evotec SE is a leading global partner in drug discovery and development services, catering to the pharmaceutical and biotechnology sectors. The company focuses on advancing pharmaceutical products across various therapeutic areas, including oncology, infectious diseases, and central nervous system disorders.

Products and Services
  • Comprehensive drug discovery and development services
  • Collaboration with major pharmaceutical companies
  • Focus on diverse therapeutic areas including oncology and immunology
Growth Outlook
  • Strong partnerships with industry leaders like Bayer and Pfizer
  • Expanding portfolio in high-demand therapeutic areas
  • Increased investment in research and development initiatives
Financial Highlights
  • Recent quarterly revenue of 143 million EUR, showing resilience
  • Trailing twelve months (TTM) revenue of 1.1 billion EUR
  • Current ratio of 2.33 indicates strong liquidity position
Evotec SE has established itself as a significant player in the healthcare sector, particularly in drug development. The company's extensive collaborations with leading pharmaceutical firms enhance its capabilities and market reach. Recent financial performance indicates a solid revenue stream, with a TTM revenue of 1.1 billion EUR, reflecting the company's operational scale. The current ratio of 2.33 suggests a robust liquidity position, allowing for continued investment in growth and innovation. As the demand for effective therapies rises, Evotec's strategic focus on diverse therapeutic areas positions it well for future growth.
AI Generated • Sep 27, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

4,461

CEO

Christian Wojczewski, PhD

Website

www.evotec.com

Headquarters

Hamburg, HA 22419, DE

EVOTF Financials

Key Financial Metrics (TTM)

Gross Margin

10.49%

Operating Margin

-17.68%

Net Income Margin

-27.47%

Return on Equity

-26.46%

Return on Capital

-11.17%

Return on Assets

-12.52%

Earnings Yield

-38.91%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$590.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

177.59M

Volume

77.70K

Avg. Volume

9.62K

Financials (TTM)

Gross Profit

€75.22M

Operating Income

-€126.93M

EBITDA

-€27.96M

Operating Cash Flow

-€113.71M

Capital Expenditure

-€48.18M

Free Cash Flow

-€161.89M

Cash & ST Invst.

€464.89M

Total Debt

€475.15M

Evotec Se Performance Analysis

Evotec Se annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 789,752,5488.1%
20232023-12-31EUR 844,811,8417.0%
20242024-12-31EUR 862,071,8372.0%
20252025-12-31EUR 889,740,3853.2%
Evotec Se sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-4.3%
Q42025-12-3154.5%
Q12026-03-31-37.9%
Q22026-06-30-8.9%
Evotec Se annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -1.04N/A
20232023-12-31EUR -0.51-50.9%
20242024-12-31EUR -1.20133.3%
20252025-12-31EUR -0.66-45.0%
Evotec Se sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31134.3%
Q12026-03-31-938.4%
Q22026-06-3062.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€143.26M

-16.3%

Gross Profit

-€1.58M

-118.4%

Gross Margin

-1.10%

N/A

Market Cap

$590.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$129.69K

N/A

Employees

4,553

N/A

Net Income

-€46.58M

-7.1%

EBITDA

-€26.65M

+28.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€464.89M

+30.4%

Total Debt

€475.15M

-12.7%

Accounts Receivable

€166.21M

-1.4%

Inventory

€38.51M

+11.4%

Long Term Debt

€413.70M

-1.1%

Short Term Debt

€61.45M

-51.2%

Return on Assets

-12.52%

N/A

Return on Invested Capital

-10.05%

N/A

Free Cash Flow

-€116.77M

-4431.1%

Operating Cash Flow

-€107.66M

-505.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PCRXPacira BioSciences, Inc.
$36.31-0.11%
BCRXBioCryst Pharmaceuticals, Inc.
$8.07-3.47%
RGCRegencell Bioscience Holdings Limited
$8.19+14.87%
HKMPFHikma Pharmaceuticals PLC
$21.06+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$14.72-6.48%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$127.57-0.65%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$33.99+1.06%

Questions About EVOTF

What is the current price of Evotec Se?

Evotec Se is trading at $3.33 per share.

What is the 52-week range for Evotec Se?

Over the past 52 weeks, Evotec Se has traded between $3.33 and $8.36.

How much debt does Evotec Se have?

As of the most recent reporting period, Evotec Se reported total debt of €544.06M.

How much cash does Evotec Se have on hand?

Evotec Se reported €398.28M in cash and cash equivalents in its most recent financial results.

What is Evotec Se’s dividend yield?

Evotec Se does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services